Amgen, MariTide and weight loss

Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) looks to get in
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering Maritime—that is,
Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug
Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.
Amgen begins late-stage trials for obesity therapy
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational ...
Fierce Biotech1d
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
Amgen (NASDAQ:AMGN) Price Target Raised to $294.00
Amgen (NASDAQ:AMGN – Free Report) had its price objective raised by Bank of America from $275.00 to $294.00 in a report released on Wednesday morning,Benzinga reports. Bank of America currently has an ...
Amgen (NasdaqGS:AMGN) Declares US$2 Dividend Per Share For Q2 2025
Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
JD Supra1d
Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 and Anti-CTLA-4 Antibody Combination Method of Treatment Patents
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
Dividend Roundup: Nvidia, Amgen, Home Depot, JD.com, and more
This week's dividend activity included increased payouts from Bestbuy (BBY) and JD.com (NASDAQ:JD) as well as declarations ...
Pacific Coast Business Times1d
Amgen shares up on obesity drug news
Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...
2 Dividend Stocks to Buy for a Lifetime of Passive Income
The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...